MedPath
HSA Approval

ROBITUSSIN EX SYRUP 200 mg/10 ml

SIN12140P

ROBITUSSIN EX SYRUP 200 mg/10 ml

ROBITUSSIN EX SYRUP 200 mg/10 ml

December 2, 2002

GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.

GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.
Licence HolderGSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05CA03

guaifenesin

Manufacturer Information

gsk consumer healthcare singapore pte. ltd.

Olic (Thailand) Limited

Active Ingredients

GUAIPHENESIN

200 mg/10 ml

Guaifenesin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ROBITUSSIN EX SYRUP 200 mg/10 ml - HSA Approval | MedPath